Medtronic PLC (NYSE:MDT) Stock Has Average Price Target of $102.88 According to Brokerages

Shares of Medtronic PLC (NYSE:MDT – Get Free Report) have been given an average rating of “Moderate Buy” by the twenty-eight brokerages that are currently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, nine have assigned a hold recommendation and eighteen have given a buy recommendation to the company. The average 1-year target price among analysts that have covered the stock in the last year is $102.88.

Several equities analysts have recently weighed in on the stock. Piper Sandler restated a “neutral” rating on shares of Medtronic in a research report on Wednesday, October 14th. Needham & Company LLC restated a “buy” rating on shares of Medtronic in a research report on Thursday, September 17th. Mizuho set a $115.00 target price on Medtronic in a research note on Wednesday, September 2nd. UBS Group reiterated a “cautious” rating on shares of Medtronic in a report on Wednesday, October 14th. Finally, Barclays raised shares of Medtronic to a “hold” rating in a research report on Wednesday, October 7th.

Read Our Latest Stock Report on MDT

Medtronic Stock Performance

MDT stock opened at $101.82 on Wednesday. The company has a 50-day simple moving average of $92.70 and a 200 day simple moving average of $88.45. The company has a market capitalization of $130.24 billion, a P/E ratio of 25.08, a PEG ratio of 2.38 and a beta of 0.56. Medtronic has a fifty-two week low of $73.31 and a fifty-two week high of $106.33. The company has a quick ratio of 1.54, a current ratio of 2.07 and a debt-to-equity ratio of 0.50.

Medtronic (NYSE:MDT – Get Free Report) last posted its quarterly earnings data on Tuesday, September 1st. The medical technology company reported $1.45 EPS for the quarter, beating analysts’ consensus estimates of $1.39 by $0.06. Medtronic had a net margin of 13.93% and a return on equity of 14.78%. The business had revenue of $9.76 billion for the quarter, compared to analyst estimates of $9.55 billion. During the same quarter last year, the business earned $1.26 earnings per share. The business’s revenue for the quarter was up 13.7% on a year-over-year basis. Medtronic has set its Q2 2027 guidance at 1.320-1.340 EPS and its FY 2027 guidance at 5.940-6.000 EPS. Sell-side analysts predict that Medtronic will post 5.98 earnings per share for the current fiscal year.

Medtronic Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Friday, October 16th. Shareholders of record on Friday, September 25th were paid a $0.72 dividend. This represents a $2.88 annualized dividend and a yield of 2.8%. The ex-dividend date was Friday, September 25th. Medtronic’s dividend payout ratio is currently 70.94%.

Insiders Place Their Bets

In other news, CEO Geoffrey Martha sold 50,000 shares of the business’s stock in a transaction on Thursday, October 15th. The shares were sold at an average price of $95.00, for a total transaction of $4,750,000.00. Following the transaction, the chief executive officer directly owned 277,866 shares in the company, valued at $26,397,270. The trade was a 15.25% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael Marinaro sold 10,420 shares of the company’s stock in a transaction on Thursday, October 15th. The stock was sold at an average price of $96.00, for a total transaction of $1,000,320.00. Following the completion of the transaction, the executive vice president directly owned 105,916 shares in the company, valued at $10,167,936. This trade represents a 8.96% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 61,903 shares of company stock worth $5,889,203 in the last quarter. 0.27% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the company. WCM Investment Management LLC acquired a new position in shares of Medtronic in the first quarter valued at approximately $965,922,000. First Eagle Investment Management LLC increased its position in shares of Medtronic by 37.2% during the second quarter. First Eagle Investment Management LLC now owns 13,783,983 shares of the medical technology company’s stock worth $1,078,321,000 after acquiring an additional 3,739,288 shares in the last quarter. Cullen Capital Management LLC acquired a new stake in shares of Medtronic during the second quarter worth $202,764,000. State Street Corp raised its holdings in shares of Medtronic by 2.7% during the second quarter. State Street Corp now owns 63,399,315 shares of the medical technology company’s stock worth $5,005,320,000 after acquiring an additional 1,658,301 shares during the period. Finally, Amundi lifted its position in Medtronic by 36.3% in the 1st quarter. Amundi now owns 6,070,236 shares of the medical technology company’s stock valued at $525,986,000 after acquiring an additional 1,616,739 shares in the last quarter. Hedge funds and other institutional investors own 82.06% of the company’s stock.

Medtronic Company Profile

(Get Free Report)

Medtronic plc is a medical technology company that develops and manufactures devices and therapies for a range of health conditions. Its products include pacemakers and defibrillators, heart valves, surgical technologies, neurostimulation devices, and insulin pumps and other diabetes-management products.

The company was founded in Minneapolis in 1949 by Earl Bakken and Palmer Hermundslie as a medical equipment repair business. It has since grown into a global company serving patients and health care providers in more than 150 countries.

Medtronic is headquartered in Dublin, Ireland, and maintains significant operations in Minnesota, where the company was founded.

Featured Stories

Analyst Recommendations for Medtronic (NYSE:MDT)

Receive News & Ratings for Medtronic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medtronic and related companies with MarketBeat.com's FREE daily email newsletter.